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OBJECTIVES To evaluate the effects of an angiotensin (Ang II) type 1 receptor antagonist on immune
markers in patients with congestive heart failure (CHF).
BACKGROUND Ang II stimulates production of immune factors via the Ang II type 1 receptor in vitro, and
the long-term effects of Ang II type 1 receptor antagonists on plasma markers of immune
activation are unknown in patients with CHF.
METHODS Twenty-three patients with mild to moderate CHF with left ventricular dysfunction were
randomly divided into two groups: treatment with Ang II type 1 receptor (candesartan
cilexetil) (n 5 14) or placebo (n 5 9). We measured plasma levels of immune factors such as
tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), soluble intercellular adhesion
molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1). We also
measured plasma levels of the neurohumoral factors such as atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP) and cyclic guanosine monophosphate (cGMP), a
biological marker of ANP and BNP.
RESULTS Plasma levels of TNFalpha, IL-6, sICAM-1 and sVCAM-1 were increased in the 23 CHF
patients compared with normal subjects and significantly decreased after 14 weeks of
candesartan cilexetil treatment, but did not change in the placebo group. Plasma levels of
BNP, which is a marker of ventricular injury, significantly decreased, and the molar ratio of
plasma cGMP to cardiac natriuretic peptides (ANP 1 BNP) was significantly increased after
candesartan cilexetil treatment, but did not change in the placebo group.
CONCLUSIONS These findings suggest that 14 weeks of treatment with an Ang II type 1 receptor antagonist
(candesartan cilexetil) decreased plasma levels of the immune markers such as TNFalpha,
IL-6, sICAM-1 and sVCAM-1 and that it improved the biological compensatory action of
endogenous cardiac natriuretic peptides in patients with mild to moderate CHF. (J Am Coll
Cardiol 2000;35:714–21) © 2000 by the American College of Cardiology
The outstanding success of angiotensin-converting enzyme
(ACE) inhibitors in the treatment of congestive heart
failure (CHF) has led to an interest in alternative ways to
block the renin-angiotensin system (1–4). Nonpeptide an-
giotensin II (Ang II) receptor antagonists such as candesar-
tan cilexetil can selectively block the Ang II type I receptor
without increasing bradykinin levels. Since Ang II may be
produced by alternative pathways (5), such drugs may have
additional advantages over ACE inhibitors, which result in
incomplete blockage of the effects of Ang II. Thus, blocking
the actions of Ang II at the receptor level represents an
attractive approach to the treatment of CHF.
Neurohumoral factors such as the renin angiotensin
system and sympathetic nervous system are generally acti-
vated in patients with CHF, and the inhibition of these
vasoconstrictive factors using ACE inhibitors and beta-
adrenergic blocking agents has been shown to improve the
prognosis of CHF patients, suggesting the important role of
these neurohumoral factors in the pathogenesis of CHF
(6–11). Recently, not only neurohumoral factors, but also
the immune system has been shown to be activated in CHF
(12–14). Proinflammatory cytokines such as tumor necrosis
factor alpha (TNFalpha) and interleukin-6 (IL-6) which
have an important role in ventricular function and ventric-
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ular remodeling (15–21), are increased in plasma in CHF
patients (12,22,23). Therefore, therapy for modulation of
such cytokines has been tested in CHF patients.
Recently, Ang II, an important component of the renin-
angiotensin system, has been shown to stimulate the pro-
duction of cytokines such as TNFalpha and IL-6 via the
Ang II type I receptor, which is present on monocytes,
macrophages and vascular smooth muscle cells (24–26).
Increased levels of TNFalpha and IL-6 in the plasma are
partly derived from production by activation of the Ang II
type I receptor. Ang II also directly, or indirectly, stimulates
the expression of intercellular adhesion molecule (ICAM-1)
and vascular cell adhesion molecule (VCAM-1) (27).
Therefore, Ang II type 1 receptor antagonists may improve
the immune activation in patients with CHF.
Plasma levels of cardiac natriuretic peptides such as atrial
natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) are increased and are useful prognostic predictors in
patients with CHF, especially BNP (28–30), which is a
ventricular hormone (31). The usefulness of plasma BNP is
partly due to the fact that high levels of BNP are signifi-
cantly correlated with hemodynamic abnormalities such as
left ventricular ejection fraction (LVEF) and left ventricular
end-diastolic pressure. Moreover, the downregulation of
cardiac natriuretic peptide receptors coupled with guanylate
cyclase may contribute to the progression of CHF (32–34).
Recently, we reported that long-term treatment with an
Ang II type 1 receptor (candesartan cilexetil) improved the
generation of plasma cyclic guanosine monophosphate
(cGMP), a biological marker of ANP and BNP (35), in
canine CHF induced by rapid ventricular pacing (36).
In this study, we evaluated the effects of 14 weeks of
treatment with candesartan cilexetil the plasma levels of
immune markers such as TNFalpha, IL-6, soluble intercel-
lular adhesion molecule-1 (sICAM-1), and soluble vascular
adhesion molecule-1 (sVCAM-1) and also determined the
effects of this treatment on the relationship between the
plasma levels of cardiac natriuretic peptides and plasma
cGMP, used as their biological markers.
METHODS
Patients. We studied 23 patients with stable symptomatic
CHF (New York Heart Association [NYHA] functional
classification of II and III) and LVEF of ,45%. There were
19 men and 4 women, and the mean age was 58 years. The
cause of heart failure was dilated cardiomyopathy in 15
patients, and 8 patients had suffered a myocardial infarction
more than six months before the study. Patients with angina
pectoris, renal failure or liver dysfunction were excluded.
Informed consent was obtained from all patients before
participation in the study, and the protocol was approved by
the Human Investigations Committee of our institution.
Fifteen patients were classified according to the standards of
the NYHA as functional class II, and eight patients as class
III. At entry to the study, 20 patients were treated with
diuretics, 11 with ACE inhibitors, 18 with digitalis and 4
with beta-blockers. Angiotensin-converting enzyme inhib-
itors were discontinued at least two weeks before the study.
Study protocol. All patients were in stable condition for at
least six months, and ACE inhibitors were not given for at
least two weeks before the study. Eleven patients had
received ACE inhibitors before the study, and these were
withheld for at least two weeks before the study. The 23
patients with mild to moderate symptomatic left ventricular
dysfunction were randomly divided into two groups: treat-
ment with candesartan cilexetil (n 5 14) or placebo (n 5 9).
Candesartan cilexetil was administered orally after a placebo
run-in period of more than two weeks. The initial dosage of
candesartan cilexetil was 2 mg once daily, which could be
increased up to a maximum of 8 mg once daily.
Blood samples used to measure the plasma levels of
neurohumoral factors and immune factors were collected
from the antecubital vein after the supine position for at
least 30 min before and after 14 weeks of treatment with
candesartan cilexetil or placebo. Blood samples were col-
lected 3 h after the oral administration on the morning of
medications such as digitalis and diuretics, before the
treatment with candesartan cilexetil or placebo. After 14
weeks of treatment with candesartan cilexetil or placebo,
blood samples were also collected 3 h after administration
on the morning of oral medications such as digitalis and
diuretics, without candesartan cilexetil or placebo. M-mode
echocardiography was also performed with two-dimensional
monitoring using a Sonolayer phased-array sector scanner
(model SSH-160A, Toshiba Co., Tokyo, Japan) before and
after 14 weeks of treatment with candesartan cilexetil or
placebo. Left ventricular volumes were calculated using
Teichholtz’s formula, and LVEF was determined.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ALD 5 aldosterone
Ang II 5 angiotensin II
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
cGMP 5 cyclic guanosine monophosphate
CHF 5 congestive heart failure
ET-1 5 endothelin-1
ICAM-1 5 intercellular adhesion molecule-1
IL-6 5 interleukin-6
LVEF 5 left ventricular ejection fraction
NE 5 norepinephrine
NYHA 5 New York Heart Association
PARC 5 plasma active renin concentration
sICAM-1 5 soluble intercellular adhesion molecule-1
sVCAM-1 5 soluble vascular adhesion molecule-1
TNFalpha 5 tumor necrosis factor alpha
VCAM-1 5 vascular cell adhesion molecule-1
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Measurement of neurohumoral factors and immune fac-
tors. Blood for the measurement of the plasma levels of
ANP, BNP, endothelin-1 (ET-1), IL-6, TNFalpha,
sICAM-1 and sVCAM-1 was transferred to a chilled tube
containing EDTA (1 mg/ml) and aprotinin (500 kallikrein
inactivator units/ml) and then centrifuged at 3,000 rpm for
15 min at 4°C. The plasma thus obtained was stored at
230°C until assayed. Plasma ANP concentrations were
measured with a specific immunoradiometric assay for
alpha-human ANP using a commercial kit (Shionoria,
Osaka, Japan) as previously reported (30). Plasma BNP
concentrations were measured with a specific immunoradio-
metric assay for human BNP using a commercial kit
(Shionoria) as previously reported (30). The plasma ET-1
level was determined using an antibody directed against
synthetic ET-1 (Peninsula Laboratories, Inc., Belmont,
California) and 125I ET-1 (Amersham Japan, Tokyo, Japan)
as previously reported (37).
Plasma levels of IL-6, TNFalpha, sICAM-1 and
sVCAM-1 were measured using commercially available
immunoassay kits (Quantikine HS, R&D Systems, Minne-
apolis, Minnesota) as previously reported (23,38). In age-
matched normal subjects (n 5 13), the plasma levels of
IL-6, TNFalpha, sICAM-1 and sVCAM-1 were 1.2 6 0.2
pg/mL, 2.7 6 0.4 pg/mL, 149 6 7 ng/mL and 530 6 38
ng/mL, respectively.
Blood specimens for the assay of plasma cGMP concen-
trations were transferred to a chilled disposable tube con-
taining 5 mmol/L EDTA. Aliquots of plasma were mea-
sured by radioimmunoassay with a commercial kit (Yamasa
Shoyu Co. Ltd., Tokyo, Japan) as previously reported (33).
Blood for measurement of the plasma levels of norepineph-
rine (NE), plasma active renin concentration (PARC), Ang
II and aldosterone (ALD) was transferred to a chilled tube
containing EDTA (1 mg/ml), centrifuged at 3,000 rpm for
15 min at 4°C, and the plasma thus obtained was stored at
230°C until assayed. Plasma NE concentration was mea-
sured by high-performance liquid chromatography. Plasma
Ang II levels were measured by a radioimmunoassay using a
specific antibody directed against synthetic Ang II (Special
Research Laboratory, Tokyo, Japan) as previously reported
(37). Plasma active renin concentration and ALD levels
were measured using commercial radioimmunoassay kits.
Statistical analysis. All results are expressed as the mean 6
SEM. Univariate analyses were performed using Student t
test. Categoric data were compared against a chi-squared
distribution. Linear regression analysis was used to deter-
mine the relationship between continuous variables. A p
value ,0.05 was regarded as significant.
RESULTS
Patient characteristics. There was no difference of age,
gender, NYHA functional class, etiology of heart failure,
LVEF or medications at entry into the study between the
candesartan group and the placebo group (Table 1).
Comparison of hemodynamics, neurohumoral factors
and immune factors before treatment between candesar-
tan cilexetil group and placebo group (Table 2). There
was no difference in heart rate, mean blood pressure or left
ventricular volume before treatment between the candesar-
tan cilexetil group and placebo group (Table 2), and there
was no difference in neurohumoral factors such as ANP,
Table 1. Patient Characteristics of 23 CHF Patients Divided Into Two Groups: Candesartan
Cilexetil Treatment or Placebo
Candesartan
Cilexetil
(n 5 14)
Placebo
(n 5 9)
p
Value
Age (years) 55.6 6 3.3 59.9 6 3.2 NS
Gender (male/female) 13/1 6/3 NS
Etiology of left ventricular dysfunction
Dilated cardiomyopathy 10 5 NS
Ischemic cardiomyopathy 4 4 NS
NYHA functional class
II 9 6 NS
III 5 3 NS
Left ventricular ejection fraction (%) 37 6 3.7 38 6 2.3 NS
Treatment
Diuretics 13 8 NS
Digitalis 11 6 NS
Beta-blockers 2 2 NS
Pretreatment
ACE inhibitors 6 5 NS
ACE 5 angiotensin converting enzyme; CHF 5 congestive heart failure; NS 5 not significant; NYHA 5 New York Heart
Association.
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BNP, cGMP, ET-1, NE, PARC, Ang II or ALD before
treatment between the two groups. There was also no
difference in immune markers such as IL-6, TNFalpha,
sICAM-1 and sVCAM-1 before treatment between the
two groups, but the levels of these immune factors were
significantly increased compared with the age-matched
normal subjects.
Chronic effects of candesartan cilexetil on hemodynam-
ics, neurohumoral factors and the immune factors. The
mean dose of candesartan cilexetil was 6.3 6 0.5 mg. In the
placebo group, there was no significant change of NYHA
functional class, heart rate, mean blood pressure or LVEF
after 14 weeks. There was also no significant change in
neurohumoral factors such as ANP, BNP, cGMP, ET-1,
PARC, Ang II or ALD or immune markers such as IL-6,
TNFalpha, sICAM-1 or sVCAM-1 after 14 weeks. In the
candesartan cilexetil group, the mean blood pressure was
significantly decreased without a change of heart rate, and
LVEF was significantly increased with the improvement of
functional class (2.4 6 0.17 vs. 1.9 6 0.16, p , 0.01) after
14 weeks (Fig. 1). Plasma active renin concentration and
Ang II levels were significantly increased; plasma ALD was
slightly decreased, and plasma NE was slightly decreased in
spite of the significant decrease of mean blood pressure (Fig.
2). The plasma levels of ANP, cGMP and ET-1 were not
changed, but plasma BNP was significantly decreased (Fig.
3). The plasma levels of IL-6, TNFalpha, sICAM-1 and
sVCAM-1 were significantly decreased (Fig. 4).
Relationship between plasma levels of cardiac natriuretic
peptides and cyclic GMP, a second messenger of cardiac
natriuretic peptides, before and after treatment with
candesartan cilexetil. There were significant positive cor-
relations between the plasma levels of cardiac natriuretic
peptides (ANP 1 BNP) and plasma cGMP levels before
and after the treatment with candesartan cilexetil or placebo.
The molar ratio of plasma cGMP to cardiac natriuretic
peptides (ANP 1 BNP) was significantly increased after
candesartan cilexetil treatment, but did not change in the
placebo group (Fig. 5).
DISCUSSION
We demonstrated that 14 weeks of treatment with an Ang
II type 1 receptor antagonist (candesartan cilexetil) signifi-
cantly decreased immune markers such as plasma levels of
TNFalpha, IL-6, sICAM-1 and sVCAM-1 in patients
with mild to moderate CHF. Recently, Ang II, an impor-
tant component of the renin-angiotensin system, was shown
to stimulate the production of cytokines such as TNFalpha
and IL-6 via the Ang II type I receptor, which is present on
monocytes, macrophages and vascular smooth muscle cells
(24–26). Ang II also stimulates the expression of ICAM-1
and VCAM-1 in vivo (27). Therefore, these decreases of the
immune markers may be direct effects of the Ang II type I
receptor antagonism of candesartan cilexetil.
We previously reported that the possibility of downregu-
lation of cardiac natriuretic peptides receptor coupled with
Table 2. Comparison of Hemodynamics, Neurohumoral Factors and Immune Factors Before
Treatment in 23 CHF Patients Divided Into Two Groups: Candesartan Cilexetil Treatment or
Placebo
Candesartan
Cilexetil
(n 5 14)
Placebo
(n 5 9)
p
Value
HR (beats/min) 77.9 6 5.7 66.8 6 2.6 NS
MBP (mm Hg) 88.7 6 3.4 87.8 6 3.5 NS
LVEDV (mL) 285 6 21 265 6 26 NS
LVESV (mL) 204 6 23 180 6 20 NS
ANP (pg/mL) 69.2 6 15.3 79.2 6 23.9 NS
BNP (pg/mL) 163.1 6 49.4 113.2 6 26.2 NS
cGMP (pmol/mL) 6.4 6 1.1 6.7 6 1.2 NS
PARC (pg/mL) 57 6 17 60 6 19 NS
Ang II (pg/mL) 41 6 8.4 45 6 9.3 NS
ALD (pg/mL) 138 6 29 132 6 62 NS
NE (pg/mL) 399 6 44 284 6 45 NS
ET-1 (pg/mL) 1.9 6 0.2 1.9 6 0.2 NS
IL-6 (pg/mL) 4.1 6 0.6 2.6 6 0.4 NS
TNF alpha (pg/mL) 5.4 6 0.4 7.2 6 1.4 NS
sICAM-1 (ng/mL) 322 6 31 236 6 20 NS
sVCAM-1 (ng/mL) 865 6 77 734 6 89 NS
ALD 5 aldosterone; Ang II 5 angiotensin II; ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; cGMP 5
cyclic guanosine monophosphate; ET-1 5 endothelin-1; HR 5 heart rate; IL-6 5 interleukin-6; LVEDV 5 left ventricular
end-diastolic volume; LVESV 5 left ventricular end-systolic volume; MBP 5 mean blood pressure; NE 5 norepinephrine;
PARC 5 plasma active renin concentration; sICAM-1 5 soluble intercellular adhesion molecule-1; sVCAM-1 5 soluble
vascular cell adhesion molecule-1; TNF 5 tumor necrosis factor.
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guanylate cyclase may contribute to the progression of CHF
(30,32–34). In this study, we showed that the molar ratio of
plasma cGMP to cardiac natriuretic peptides was signifi-
cantly increased after candesartan cilexetil treatment, sug-
gesting that candesartan cilexetil improved the biological
compensatory action of endogenous cardiac natriuretic pep-
tides in patients with mild to moderate CHF, as previously
shown in canine CHF (36). The mechanism of the im-
provement of the relationship between cardiac natriuretic
peptides and cGMP after candesartan cilexetil treatment is
partly due to the fact that Ang II reduces cGMP accumu-
lation produced by cardiac natriuretic peptides in target cells
by the activation of phosphodiesterase (39).
Recently, losartan has been shown to produce an unex-
pectedly lower risk of mortality than ACE inhibitors in
older patients with CHF, suggesting the usefulness of Ang
II receptor antagonists (4). Considering this along with our
findings, it might be useful to determine in future studies
the relationship of changes in cytokines and adhesion
molecules to the effects of Ang II inhibition on ventricular
remodeling and prognosis. We have reported that plasma
levels of sICAM-1 are increased with the severity of CHF
and can provide prognostic information in patients with
CHF (38). The evaluation of the levels of adhesion mole-
cules may yield important information about the activation
of the immune system, since molecules such as ICAM-1
and VCAM-1 affect the biological activity of leukocytes and
various cytokines which stimulate the expression of
ICAM-1 or VCAM-1 in target cells. The mechanism of
Figure 1. Hemodynamic parameters and functional class before and after 14 weeks of treatment with candesartan cilexetil in 14 patients
with mild to moderate congestive heart failure. HR 5 heart rate; LVEDV 5 left ventricular end-diastolic volume; LVEF 5 left ventricular
ejection fraction; LVESV 5 left ventricular end-systolic volume; MBP 5 mean blood pressure; NYHA 5 New York Heart Association.
*p , 0.05; **p , 0.01 vs. before.
Figure 2. Plasma levels of active renin concentration (PARC),
angiotensin (Ang II), aldosterone (ALD) and norepinephrine
(NE) before and after 14 weeks of treatment with candesartan
cilexetil in 14 patients with mild to moderate congestive heart
failure. *p , 0.05; **p , 0.01 vs. before.
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the decrease of sICAM-1 and sVCAM-1 after candesartan
cilexetil treatment is mainly due to the decreases of TNFal-
pha and IL-6, which stimulate the expression of sICAM-1
and sVCAM-1 in vitro.
In this study, the plasma Ang II level was significantly
increased after candesartan cilexetil treatment, which is
consistent with the reports of previous studies. Recent
studies have suggested that the Ang II type 1 receptor is
downregulated and the Ang II type 2 receptor is upregu-
lated in the failing human ventricle (40). The pathophysi-
ological role of Ang II type 2 receptors has not been fully
clarified; the increase of plasma Ang II after treatment with
Ang II type 1 receptor antagonists may inhibit interstitial
fibrosis via upregulated Ang II type 2 receptors in fibroblasts
and, thereby, have beneficial effects on ventricular remod-
eling (40). In this study, the significant decrease of mean
blood pressure and left ventricular end-systolic volume was
probably due to the vasodilatory action via the Ang II type
1 receptor. The significant improvement of LVEF with a
slight decrease of left ventricular end-diastolic volume was
mainly due to vasodilatory action, suggesting that improve-
ment of left ventricular remodeling requires more long-term
treatments. Moreover, the increase of plasma Ang II after Ang
II type 1 receptor antagonist treatment may suppress the
production of cytokines such as TNFalpha and IL-6 via effects
on the Ang II type 2 receptors on human monocytes (41).
Study limitations. We cannot rule out the possibility that
the decrease of the plasma levels of TNFalpha, IL-6,
sICAM-1 and sVCAM-1 were due to the improvement of
hemodynamic parameters and symptoms. In general, there
were wide ranges of plasma levels of TNFalpha and IL-6 in
patients with CHF, and the levels were significantly in-
creased in patients with moderate to severe CHF. More-
over, there were no or poor correlations between plasma
Figure 3. Plasma levels of endothelin-1 (ET-1), atrial natriuretic
peptide (ANP), brain natriuretic peptide (BNP) and cyclic
guanosine monophosphate (cGMP) before and after 14 weeks of
treatment with candesartan cilexetil in 14 patients with mild to
moderate congestive heart failure. *p , 0.05 vs. before.
Figure 4. Plasma levels of interleukin-6 (IL-6), tumor necrosis
factor alpha (TNFa), soluble intercellular adhesion molecule-1
(sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1)
before and after 14 weeks of treatment with candesartan cilexetil in
14 patients with mild to moderate congestive heart failure. *p ,
0.05 vs. before.
Figure 5. The molar ratio of plasma cGMP (cyclic guanosine
monophosphate) to cardiac natriuretic peptides before and after 14
weeks of treatment with candesartan cilexetil (closed columns) or
placebo (open columns). ANOVA 5 analysis of variance; ANP 5
atrial natriuretic peptide; BNP 5 brain natriuretic peptide. *p ,
0.05 vs. before with a two-way ANOVA by Scheffe´ F test.
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cytokines and hemodynamic parameters in CHF patients.
We believe that the significant decreases of the plasma levels
of TNFalpha, IL-6, sICAM-1 and sVCAM-1 in a small
number of patients were mainly due to the direct action of
Ang II type 1 receptor antagonist because other neurohu-
moral factors, except plasma BNP, did not change signifi-
cantly. However, future studies will be needed in a larger
number of patients over a longer follow-up period to
determine whether these changes are persistent and are
found in other Ang II type 1 receptor antagonists.
Conclusions. Plasma levels of immune markers such as
TNFalpha, IL-6, sICAM-1 and sVCAM-1 were signifi-
cantly decreased after 14 weeks of candesartan cilexetil
treatment but not after treatment with placebo. We also
showed that plasma levels of BNP, which are a useful
marker of prognosis, significantly decreased, and the molar
ratio of plasma cGMP to cardiac natriuretic peptides
(ANP 1 BNP) was significantly increased after candesartan
cilexetil treatment but not after treatment in placebo,
suggesting that candesartan cilexetil improved the biological
compensatory action of endogenous cardiac natriuretic pep-
tides in patients with mild to moderate CHF. These
findings suggest that long-term treatment with the Ang II
type 1 receptor antagonist (candesartan cilexetil) improved
the activation of the immune system and improved the
biological compensatory action of endogenous cardiac na-
triuretic peptides in patients with mild to moderate CHF.
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